FSTL3 and gastric cancer: We also made a synthetic miR-486-5p inhibitor, and delivery of this into gastric cancer cells caused a 1.5-2-fold rise in FSTL3 protein levels; this correlated with a 2.5-fold rise in FSTL3 mRNA levels (Figure 5E).